2024
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease
van Dyck C, Mecca A, O’Dell R, Bartlett H, Diepenbrock N, Huang Y, Hamby M, Grundman M, Catalano S, Caggiano A, Carson R. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease. Alzheimer's Research & Therapy 2024, 16: 20. PMID: 38273408, PMCID: PMC10809445, DOI: 10.1186/s13195-024-01382-2.Peer-Reviewed Original ResearchConceptsMild to moderate dementiaPositron emission tomographyAlzheimer's diseaseVolumetric MRIModerate dementiaClinical rating scalesSynaptic vesicle glycoprotein 2ACerebrospinal fluidMouse model of ADPharmacodynamic effectsPlacebo-controlled phase 1 clinical trialBiomarkers of AD pathologyClinical trialsCognitive measuresNominally significant differencesPhase 1 clinical trialModel of ADHippocampal cortexPhase 1/2 studyRating ScaleParallel-group trialSynaptic densityTrial registrationThe clinical trialPlacebo-controlledSigma-2 receptor ligands
2013
Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke
Regenhardt RW, Desland F, Mecca AP, Pioquinto DJ, Afzal A, Mocco J, Sumners C. Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke. Neuropharmacology 2013, 71: 154-163. PMID: 23583926, PMCID: PMC3664115, DOI: 10.1016/j.neuropharm.2013.03.025.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IAnimalsAnti-Inflammatory Agents, Non-SteroidalBrain IschemiaCells, CulturedCerebral CortexDisease Models, AnimalGene Expression RegulationMaleMiceMice, Inbred StrainsMice, KnockoutMicrogliaNerve Tissue ProteinsNeuroprotective AgentsNitric OxideNitric Oxide Synthase Type IIPeptide FragmentsProto-Oncogene MasProto-Oncogene ProteinsRatsRats, Sprague-DawleyReceptors, G-Protein-CoupledSpecific Pathogen-Free OrganismsStrokeConceptsInducible nitric oxide synthaseAnti-inflammatory effectsIschemic strokeEndothelin-1Cerebral cortexMiddle cerebral artery occlusionCerebral infarct sizeDifferentiation molecule 11bIntracerebral inflammatory responseCerebral artery occlusionAnti-inflammatory actionLipopolysaccharide-induced increasePro-inflammatory cytokinesCerebral blood flowINOS protein expressionNitric oxide synthaseNitric oxide productionNitric oxide generationExpression of mRNAAng-(1-7) treatmentSignificant cerebroprotectionCerebral vasoconstrictionArtery occlusionCerebroprotective actionReceptor Mas
2005
Protection from angiotensin II‐induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats
Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM, Raizada MK. Protection from angiotensin II‐induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2005, 90: 783-790. PMID: 16049057, DOI: 10.1113/expphysiol.2005.031096.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IIAngiotensin-Converting Enzyme 2AnimalsAnimals, NewbornBlood PressureBody WeightCarboxypeptidasesCardiomyopathy, HypertrophicEndomyocardial FibrosisGene ExpressionGenetic VectorsHeartLentivirusMiceMyocardiumOrgan SizePeptidyl-Dipeptidase ARatsRats, Sprague-DawleyTransduction, GeneticConceptsRenin-angiotensin systemAngiotensin IIMyocardial fibrosisCardiac hypertrophyAngiotensin II infusionSystolic blood pressureBody weight ratioOverexpression of ACE2Potential therapeutic targetII infusionMmHg increaseBlood pressureHeart weightControl ratsDawley ratsCardiovascular diseaseEnzyme 2Protective effectTherapeutic targetMouse ACE2FibrosisHypertrophyRatsACE2Significant attenuation